Objective. Previous studies have shown that in patients with ANCA-associated vasculitis (AAV), antiplasminogen antibodies were associated with reduced renal function and the presence of fibrinoid necrosis and cellular crescents in renal histology. The purpose of the current study was to investigate whether anti-plasminogen antibodies are associated with the systemic disease activity of AAV.
Introduction
ANCA-associated vasculitis (AAV) comprises a group of disorders characterized by necrotizing small-vessel vasculitis, which includes granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic GPA (EGPA) [1, 2] . The two major antigens of ANCAs are MPO and PR3 [1, 3] .
It was found recently that plasminogen deficiency is associated with thrombotic risk [4, 5] and crescentic glomerulonephritis [6] . Plasminogen plays an important role in leukocyte recruitment and inflammatory responses [5, 7] . It has been reported that anti-plasminogen antibody in AAV is correlated with reduced renal function and the percentages of glomeruli with fibrinoid necrosis and cellular crescents [8] . However, whether there is any association between anti-plasminogen antibodies and the systemic activity of AAV is not clear. The purpose of the current study was to investigate whether anti-plasminogen antibodies are associated the systemic disease activity of AAV.
Methods

Patients
Blood samples of 104 consecutive patients with active AAV at initial onset, diagnosed at Peking University First Hospital from 2008 to 2011, were collected before commencing immunosuppressive treatment. All the patients met the Chapel Hill Consensus Conference (CHCC) definition of AAV [9] . Patients with secondary vasculitis or with co-morbid renal diseases, such as anti-GBM nephritis, IgA nephropathy, diabetic nephropathy, lupus nephritis or membranous glomerulonephropathy, were excluded. Blood samples of 48 patients with AAV who achieved remission after immunosuppressive therapy were also collected at their regular ambulatory visits. The time of sampling was 15.5 (S.D. 3.0) months after remission was achieved. All 48 patients were among the 104 patients described above. Fifty-three of the 104 received renal biopsy at diagnosis and before commencing immunosuppressive therapy. Fifty age-and gendermatched healthy blood donors were enrolled as normal controls. Twenty patients with anti-GBM disease were enrolled as disease controls. Sera from all subjects were kept at À70 C until use. The disease activity of AAV was assessed according to the BVAS [10] . Remission was defined as the 'absence of disease activity attributable to active disease qualified by the need for ongoing stable maintenance immunosuppressive therapy' (complete remission), or a '50% reduction of the disease activity score and absence of new manifestations' (partial remission), as described previously [11] . Estimated glomerular filtration rate (eGFR) was calculated using the modification of diet in renal disease equations [12] . This research was in compliance with the Declaration of Helsinki and was approved by the Clinical Research Ethics Committee of the Peking University First Hospital. Written informed consent was obtained from each participant.
Detection of serum ANCA ANCA tests were performed by both IIF assays and antigen-specific ELISAs. Standard IIF assays were performed according to the manufacturer's instructions (Euroimmun, Lü beck, Germany). Two highly purified known ANCA antigens, PR3 and MPO, purified as previously reported [13] , were used as solid-phase ligands in ELISA. Serum levels of PR3-and MPO-ANCA were measured according to the manufacturer's instructions using a commercial ELISA kit (Euroimmun, Lü beck, Germany). The results of ELISA-ANCA were expressed as relative units per millilitre.
Detection of anti-plasminogen antibodies
Anti-plasminogen antibodies were detected by following the method established previously [8, 14] . In brief, purified normal human plasminogen (Abcam, Cambridge, UK) diluted at 5 mg/ml in 0.05 M bicarbonate buffer (pH 9.6) was coated onto the wells of one-half of a polystyrene microtitre plate (Costar, Mankato, MN, USA). The wells in the other half were coated with the same bicarbonate buffer alone to act as antigen-free wells to exclude nonspecific binding. The volume of each well for this step and for subsequent steps was 100 ml. All incubations were carried out at 4 C overnight and the plates were washed three times with 0.01 M PBS containing 0.1% Tween 20 (PBST). Then the plates were blocked for 1 h with PBST containing 1% BSA at 37 C. The sera diluted at 1:100 with PBST were added in duplicate to both antigen-coated and antigen-free wells. Each plate contained a blank control, negative control and a known positive control. After incubation and washing, the wells were then incubated with 1:5000 diluted ALP-conjugated goat anti-human IgG antibody. The results were recorded as the net optical absorbance (average value of antigen wells minus average value of antigen-free wells) at 405 nm in an ELISA reader (Bio-Rad 550; Bio-Rad Laboratories, Tokyo, Japan). Positivity was defined as the mean + 2 S.D. above the mean of 50 healthy control subjects. The quantitative level of anti-plasminogen antibody was expressed as the percentage of the positive control.
Renal histopathology
Fifty-three renal biopsy specimens were evaluated using direct immunofluorescence and light and electron microscopy. For light microscopy, paraffin sections stained with silver, periodic acid-Schiff, haematoxylin and eosin, and trichrome were forwarded to two pathologists. Two pathologists who were blinded to the patients' data evaluated the slides separately, according to a previously standardized protocol for scoring renal biopsies of patients with ANCA-AAV [1517] . Differences in scoring between the two pathologists were resolved by re-reviewing the biopsies and coming to a consensus. Local segmental sclerosis, fibrinoid necrosis and crescents were calculated as percentages of the total number of glomeruli. Interstitial and tubular lesions were scored semi-quantitatively on the basis of the percentage of the tubulointerstitial compartment that was affected: interstitial infiltrate (À for 0%, + for 020%, ++ for 2050% and +++ for >50%), interstitial fibrosis (À for 0%, + for 050% and ++ for >50%) and tubular atrophy (À for 0%, + for 050% and ++ for >50%).
Statistical analysis
Quantitative data are expressed as mean (S.D.), median (range) or median [interquartile range (IQR)] or number (%) as appropriate. Differences in continuous variables between groups were assessed using the t-test (for data that were normally distributed) or non-parametric t-test (for data that were not normally distributed) as appropriate. Differences of semi-quantitative results were tested using the MannWhitney U test. Differences in categorical variables were compared using the 2 test. The Pearson test was used for correlation analysis. The probability of progressing to end-stage renal disease (ESRD) and relapse was derived from KaplanMeier analysis. Differences were considered significant if the P-value was <0.05. The statistical analysis was performed using the SPSS statistical software package (version 16.0; SPSS, Chicago, IL, USA). were found between anti-plasminogen-positive patients and anti-plasminogen-negative patients.
Anti-plasminogen antibodies in AAV patients in the active stage, remission and relapse Follow-up data were available for all 104 patients. Eleven of 104 patients died in the acute phase of AAV before remission was achieved. The other 93 patients achieved remission (complete or partial). As described above, blood samples from the remission stage of AAV were available in 48 of the 93 patients. The prevalence of anti-plasminogen antibodies was significantly higher in AAV patients with active disease than those in remission (19/ . This indicated that the association between the levels of anti-plasminogen antibodies and disease activity was closer than the association between ANCA levels and disease activity. Among the 48 AAV patients with sequential serum samples, 10 patients experienced relapses during a follow-up of 23.5 (IQR 3.2550.75) months. We further measured anti-plasminogen antibodies in sequential serum samples of these 10 patients. Only 1 of 10 patients was positive for anti-plasminogen antibodies at the relapse stage. Antiplasminogen antibodies were positive at initial presentation for that patient, which became negative in remission and positive again at subsequent relapse. For the other 38 patients who did not experienced relapse, we further measured anti-plasminogen antibodies in several serum samples per patient at different time points during remission. Anti-plasminogen antibodies in these sera were all negative.
Association between anti-plasminogen antibodies and clinicopathological parameters in AAV patients
Fibrin degradation products (FDPs), d-dimer, ANCA level, CRP, ESR and serum creatinine measurements were done at the same time as serum samples were collected for this study. Correlation analysis showed that the level of anti-plasminogen antibodies (expressed as a percentage of the positive controls) correlated with the level of ESR (r = 0.207, P = 0.042), serum creatinine (r = 0.302, P = 0.002) and d-dimer (r = 0.273, P = 0.009). The level of anti-plasminogen antibodies was negatively correlated with eGFR (r = À0.306, P = 0.002). Correlation analysis also showed that the level of anti-plasminogen antibodies correlated with the percentage of glomeruli with crescents in the renal specimens (r = 0.393, P = 0.004) (Fig. 2) . The patients with anti-plasminogen antibodies had a significantly higher level of BVAS than patients without antiplasminogen antibodies [22. 5 (S.D. 5.6) vs 19.4 (S.D. 4.7), P = 0.015]. The prevalence of arthralgia, pulmonary infiltration, gastrointestinal tract involvement and nervous system involvement in patients with anti-plasminogen antibodies was significantly higher than in patients without anti-plasminogen antibodies (63.2% vs 25.8%, P = 0.002; 63.2% vs 35.2%, P = 0.025; 57.9% vs 21.1%, P = 0.001; 36.8% vs 12.9%, P = 0.013, respectively). No significant differences in muscle pain, skin rash, ENT involvement, FDPs and dialysis-dependence at diagnosis were found in patients with or without anti-plasminogen antibodies.
The renal histopathological parameters of 53 AAV patients were further analysed ( Table 1 ). The number of glomeruli per biopsy was 23 (range 553). Fifteen of these 53 patients were positive for anti-plasminogen antibodies. The percentage of glomeruli with crescents in patients positive for anti-plasminogen antibodies was significantly higher than in patients negative for anti-plasminogen antibodies [54.7 (range 086.9) vs 21.4 (084.0), P = 0.002]. In the KaplanMeier analysis, the probability of progressing to ESRD (Fig. 3A) and relapse (Fig. 3B ) was not significantly different between patients with and without anti-plasminogen antibodies (P = 0.46 and P = 0.34, respectively).
Discussion
The concept of complementary proteinprotein interactions led to the discovery of a previously unidentified autoantigen [18, 19] . Potential cPR3m (a protein complementary to the middle part of PR3)-homologous structures were found in various pathogens, and anti-cPR3 reactivity was increased in PR3-ANCA-positive patients compared with MPO-ANCA patients [20] . These findings were disputed by Tadema et al. [21] in a separate study that failed to detect increased anti-cPR3 reactivity in PR3-ANCA-AAV patients. The anti-plasminogen antibodies reacted with a highly restricted motif on the plasminogen, also found in cPR3 105201 [14] . Meanwhile, Berden et al. [8] reported the presence and functionality of anti-plasminogen antibodies in both PR3-and MPO-ANCA patients, suggesting a discordance between anti-plasminogen and anti-cPR3 antibodies in MPO-ANCA patients. More importantly, it was found that anti-plasminogen antibodies correlate with reduced renal function and the percentages of glomeruli with fibrinoid necrosis and cellular crescents in AAV patients [8] . Thus it was reasonable to speculate that the level of serum anti-plasminogen antibodies might be associated with the systemic disease activity of AAV. We identified the anti-plasminogen antibodies in $18% of AAV patients. This prevalence was similar to two other studies [8, 14] . There was no significant difference in the prevalence of anti-plasminogen antibodies between MPO-ANCA-and PR3-ANCA-positive patients.
In AAV renal involvement, patients with anti-plasminogen antibodies had a significantly higher level of serum creatinine and higher percentages of glomeruli with cellular crescents. These results confirmed and further extended previous observations [8] . Plasminogen plays an important role in protecting the glomerulus from acute inflammatory injury [6] . Fibrin exudate is important in stimulating the crescent formation [22] . Anti-plasminogen antibodies might influence glomerular pathology through a disturbance of fibrinolysis in the microvasculature [8] .
The most important finding in the current study was that anti-plasminogen antibodies are associated with the systemic disease activity of AAV. Patients with anti-plasminogen antibodies had a significantly higher level of BVAS than those without. The serum levels of anti-plasminogen antibodies were associated with ESR. Patients with antiplasminogen antibodies had more common or more severe organ involvement, including lungs, gastrointestinal tract, nervous system and kidneys, than patients without anti-plasminogen antibodies. More importantly, it was found that the level of anti-plasminogen antibodies in remission is lower than in the active phase for every patient with sequential serum samples. Vasculitis is an inflammatory process of the blood vessels and is characterized by an influx of inflammatory cells with fibrinoid necrosis in the small vessel walls [14] . Plasminogen plays a major role in inflammatory cell recruitment [23] . Therefore we speculated that the complex of plasminogen and antiplasminogen antibodies may participate in the inflammatory reaction. Anti-plasminogen antibodies might promote the development of inflammation and disease activity in AAV. Moreover, fibrinoid necrosis is a ubiquitous feature in the histology of ANCA-AAV [24] . This disturbance might be initiated or accelerated by anti-plasminogen antibodies through a disturbance of fibrinolysis in the microvasculature [10] .
Previous studies found that anti-plasminogen antibodies can delay fibrinolysis [8] and correlated with venous thromboembolic event episodes in AAV patients [14] . Although we failed to find any correlation between antiplasminogen antibodies and venous thromboembolic events since it was retrospective study, it was found in the current study that patients with anti-plasminogen antibodies have higher levels of d-dimer than those without. This supported, at least to some extent, the relationship between anti-plasminogen antibodies and thrombotic events [14] .
One limitation of the current study was the failure to demonstrate that the levels of anti-plasminogen antibodies could predict relapse. There are several possible reasons. First, relapse events were uncommon in our cohort. That was probably because most of our patients were MPO-ANCA positive, and thus less likely to relapse compared with PR3-ANCA-positive patients. Moreover, the prevalence of anti-plasminogen antibodies was not high, even at the initial onset of AAV (19/104), let alone in relapse. Therefore it is not easy to get positive results of anti-plasminogen antibodies in a cohort without enough endpoint events (relapse). To achieve more convincing results of anti-plasminogen antibody in predicting relapse, a larger sample size, in particular, with more relapse events, is needed for further investigation. In conclusion, circulating anti-plasminogen antibodies were associated with systemic disease activity as well as renal disease activity in ANCA-AAV.
Rheumatology key messages
. Circulating anti-plasminogen antibodies were associated with the systemic disease activity of ANCA-AAV. . Circulating anti-plasminogen antibodies were associated with the renal disease activity of ANCA-AAV.
